Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed adenocarcinoma of the pancreas
Metastatic disease
Received at least two prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease.
At least one of the prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease must have contained gemcitabine and have met the following criteria:
Completed at least one cycle of the treatment
Received gemcitabine administered at a minimum dose of 800 mg/m2 per week in the first cycle of treatment
Progressed while receiving this gemcitabine regimen or within 3 months of completing gemcitabine
Progression was documented,
Preferentially radiologically by tumor growth or new lesions, or by
Clear symptomatic deterioration supported by at least two of the following clinical criteria: ≥ 10% worsening in KPS or ≥ 1 worsening in ECOG; increasing weakness or fatigue; progressive weight loss; new/worsening pain requiring increased pain medication; new/worsening jaundice, nausea, or vomiting; new/worsening ascites or pleural effusions; other physical or laboratory findings consistent with disease progression.
KPS \>/= 70
Adequate bone marrow function
Adequate hepatic function
Adequate renal function
You may not be if
CNS metastatic disease
Bulky disease (any single mass \>10 cm).
-\>Grade 2 nausea or vomiting, and/or signs of intestinal obstruction.
Prior external beam irradiation to a field that includes more than 30% of the red bone marrow.
Patients with clinically significant severe cardiorespiratory disease.
Clareo Health | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
